# A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

> **NCT03978611** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 11 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Relatlimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03978611
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-09
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-07-26
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978611, "A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03978611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*